Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;26(6):940-950.
doi: 10.1111/hiv.70030. Epub 2025 May 1.

Immune profiles and HIV reservoir in people switching to long-acting cabotegravir/rilpivirine: Findings from a real-life prospective study

Maria Mazzitelli  1 , Maria Raffaella Petrara  2 , Claudia Cozzolino  3 , Lolita Sasset  1 , Davide Leoni  1 , Elena Ruffoni  2 , Samuele Gardin  1 , Beatrice Bragato  1 , Angela Panese  1 , Vincenzo Scaglione  1 , Baldo Vincenzo  3 , Anita De Rossi  2   4 , Anna Maria Cattelan  1
Affiliations

Immune profiles and HIV reservoir in people switching to long-acting cabotegravir/rilpivirine: Findings from a real-life prospective study

Maria Mazzitelli et al. HIV Med. 2025 Jun.

Abstract

Introduction: Data on the dynamics of HIV-DNA and immune profiles under treatment with long-acting cabotegravir and rilpivirine (LACR) are limited.

Methods: We prospectively enrolled people living with HIV who initiated LACR in our centre and assessed changes in HIV-DNA levels (measured by digital droplet PCR), as well as immune activated, senescent, exhausted, and regulatory T and B cells (analysed by flow cytometry), in peripheral blood mononuclear cells (PBMC) from baseline (T0) to 48 weeks of treatment (T5). Bivariate analyses, one-way repeated measures ANOVA and mixed ANOVA were conducted to assess differences in characteristics and biomarker changes over time between individuals switching to LACR from a dual (Group A) or triple (Group B) antiretroviral regimen.

Results: A total of 71 persons were included (77.5% males, median age of 48 years). Overall, HIV-DNA levels exhibited a slight non-significant decrease, whereas activated CD8 cells decreased significantly (p < 0.001). Proportions of activated CD4 and regulatory T cells showed strong negative trends, but decreases did not reach statistical significance (p = 0.002 and 0.005). The dynamics of these markers within the two subgroups mirrored those of the entire cohort, with some differences. At baseline, Group A tended to exhibit higher levels of HIV-DNA (96 [31-160] vs. 41 [6-93] copies/106 PBMC, p = 0.088), and activated CD4 (% activated CD4 cells: 2.3 [1-2.9] vs. 1 [0.7-2], p = 0.154) and CD8 cells (% activated CD8 cells: 4.9 [2.2-5.8] vs. 2.2 [1.2-3.5], p = 0.023) than Group B. Over the 48-week treatment period, HIV-DNA levels decreased slightly in both groups, remaining higher in Group A. At the end of the 48-week treatment period, the decrease of activated CD4 and CD8 cells was more pronounced in Group A than in Group B, ultimately reaching comparable levels between the two groups (% of activated CD4 cells: 0.9 [0.6-1.9] vs. 0.7 [0.6-1.1], p = 0.502): % of CD8 activated cells: (2 [1.3-2.5] vs. 1.6 [0.9-2.2], p = 0.278).

Conclusion: During the first year of treatment, LACR does not significantly impact the HIV reservoir. However, it may reduce immune activation, particularly in persons switching from a dual therapy regimen.

Keywords: HIV; HIV‐DNA; biomarkers; inflammation; long‐acting cabotegravir and rilpivirine.

PubMed Disclaimer

References

REFERENCES

    1. Shubber Z, Mills EJ, Nachega JB, et al. Patient‐reported barriers to adherence to antiretroviral therapy: a systematic review and meta‐analysis. PLoS Med. 2016;13:e1002183.
    1. Gooden TE, Wang J, Zemedikun DT, et al. A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV. HIV Med. 2023;24:640‐647.
    1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506‐2512.
    1. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614‐622.
    1. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV‐associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087‐2096.